260 Stock Overview
A clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Centessa Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.60 |
| 52 Week High | US$16.40 |
| 52 Week Low | US$5.20 |
| Beta | 1.48 |
| 11 Month Change | 12.23% |
| 3 Month Change | 32.20% |
| 1 Year Change | 173.68% |
| 33 Year Change | 36.84% |
| 5 Year Change | n/a |
| Change since IPO | -12.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| 260 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.3% | 0.8% | 0.8% |
| 1Y | 173.7% | -18.3% | 8.6% |
Return vs Industry: 260 exceeded the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: 260 exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| 260 volatility | |
|---|---|
| 260 Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 260's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 260's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 75 | Saurabh Saha | www.centessa.com |
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy.
Centessa Pharmaceuticals plc Fundamentals Summary
| 260 fundamental statistics | |
|---|---|
| Market cap | €2.15b |
| Earnings (TTM) | -€153.93m |
| Revenue (TTM) | €6.54m |
332.8x
P/S Ratio-14.1x
P/E RatioIs 260 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 260 income statement (TTM) | |
|---|---|
| Revenue | US$6.85m |
| Cost of Revenue | US$0 |
| Gross Profit | US$6.85m |
| Other Expenses | US$168.12m |
| Earnings | -US$161.26m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.22 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,353.20% |
| Debt/Equity Ratio | 15.2% |
How did 260 perform over the long term?
See historical performance and comparison